
Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.
Atezolizumab (Tecentriq) is indicated for use in urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.
Medication Pearl of the Day: Atezolizumab (Tecentriq)
Indication: Atezolizumab (Tecentriq) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for use in urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and melanoma.
Insight:
Source






